心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
(注:?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) )
- 編號(hào)LMA225Ca
- 物種Canis familiaris; Canine (Dog,犬) 相同的名稱(chēng),不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類(lèi)型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2696 ¥ 2799 ¥ 2955 ¥ 3162 ¥ 3370 ¥ 3681 ¥ 4147 計(jì)算器 ¥ 5184 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
特異性
本試劑盒用于檢測(cè)心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 89-103 | 95 |
EDTA plasma(n=5) | 99-105 | 102 |
heparin plasma(n=5) | 79-103 | 95 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 94-101% | 85-102% | 78-93% | 92-104% |
EDTA plasma(n=5) | 79-94% | 80-101% | 87-94% | 97-105% |
heparin plasma(n=5) | 83-102% | 89-103% | 91-101% | 80-98% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A)標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL,加檢測(cè)溶液A50μL,
37°C酶標(biāo)板振蕩器孵育60分鐘;
3. 磁吸洗板3次;
4. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
5. 磁吸洗板3次;
6. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA,標(biāo)記的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合,然后將未結(jié)合物洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Canis familiaris; Canine (Dog,犬) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA225Ca01 | 心鈉肽(ANP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
CPA225Ca21 | 心鈉肽(ANP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
PAA225Ca01 | 心鈉肽(ANP)多克隆抗體 | WB; IHC; ICC; IP. |
PAA225Ca08 | 心鈉肽(ANP)多克隆抗體 | WB; IHC; ICC; IP. |
MAA225Ca21 | 心鈉肽(ANP)單克隆抗體 | WB; IHC; ICC; IP. |
CEA225Ca | 心鈉肽(ANP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA225Ca | 心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function [PubMed: 21616283] |
Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery [PubMed: 21769675] |
Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients [PubMed: 23406607] |
European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment. [Pubmed: 24356727] |
Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx [Pubmed:25497357] |
Diabet Med.? | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes. [Pubmed:26927445] |
J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway [Pubmed:26970569] |
Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease. [papers:uobj_paper_2016_62613672.pdf] |
PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy [pubmed:29240788] |
Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy. [pubmed:29063791] |
Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation [Pubmed:29504933] |
Science?of the?Total?Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and [Pubmed:29727991] |
The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice [Pubmed:29929978] |
Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease [Pubmed:29392348] |
FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |
Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension?… [Pubmed: 30359461] |
International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma [] |
Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure. [] |
Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy [34094834] |
Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy [34624429] |
Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress [Pubmed:35218795] |